Calcium-channel blockers and the gastrointestinal tract. American College of Gastroenterology's Committee on FDA related matters.
D000818:Animals; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology*; D004064:Digestive System / Q000187:drug effects*; D004110:Diltiazem / Q000494:pharmacology; D004931:Esophageal Achalasia / Q000503:physiopathology; D004935:Esophageal Diseases / Q000188:drug therapy; D004943:Esophagogastric Junction / Q000187:drug effects / Q000502:physiology; D004947:Esophagus / Q000187:drug effects / Q000502:physiology; D005744:Gastric Acid / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000502:physiology; D008099:Liver / Q000187:drug effects; D009543:Nifedipine / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects; D011312:Pressure; D013270:Stomach / Q000187:drug effects / Q000502:physiology; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine